Bristol Myers Squibb wins first FDA approval for a CELMoD therapy
Bristol Myers Squibb has secured accelerated approval from the United States Food and Drug Administration for Zenbexus, making iberdomide the first therapy from the company’s CELMoD class to reach the US market. The oral drug was approved as part of a three-drug regimen with subcutaneous daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma
